| AGEs | Advanced glycation end-products |
| Akt | Protein kinase B |
| AMP | Adenosine monophosphate |
| ATP | Adenosine triphosphate |
| cAMP | 3′,5′-cyclic AMP |
| DPP4 | Dipeptidyl peptidase 4 |
| ERK | Extracellular signal-regulated kinase |
| FAERS | FDA advance event reporting system |
| FDA | Food and drug administration |
| GIP | GIP receptor |
| GIP | Glucose-dependent insulinotropic polypeptide/Gastric inhibitory peptide |
| GLP-1 | Glucagon-like peptide 1 |
| GLP-1R | GLP-1 receptor |
| IGF-1R | IGF-1 receptor |
| IGF-BP3 | Insulin-like growth factor binding protein 3 |
| IGF1/2 | Insulin-like growth factor 1/2 |
| JAK | Janus kinase |
| MAPK | Mitogen activated protein kinase |
| MEN2 | Multiple endocrine neoplasia syndrome type 2 |
| MTC | Medullary thyroid cancer/carcinoma |
| mTOR | mammalian target of rapamycin |
| NF-κB | Nuclear factor kappa-B |
| PARP | Poly (ADP-ribose) polymerase |
| PI3K | Phosphoinositide 3-kinase |
| PSMA2 | Proteasome alpha 2 subunit |
| RAGEs | Receptors of AGEs |
| SGLT2 | Sodium glucose co-transporter 2 |
| STAT | Signal Transducer and Activator of Transcription |
| TRZD | Tirzepatide |
| WHO | World Health Organization |